[Adalimumab in Crohn's disease - data from real life]

Rev Esp Enferm Dig. 2008 Nov;100(11):671-5. doi: 10.4321/s1130-01082008001100001.
[Article in Spanish]
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Adalimumab
  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / therapeutic use*
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Crohn Disease / drug therapy*
  • Follow-Up Studies
  • Humans
  • Infliximab
  • Randomized Controlled Trials as Topic / statistics & numerical data
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Adalimumab